Echopoint raises £2.8m to address the ‘grey zone’ of heart disease treatment
Echopoint Medical Ltd, a spinout company from UCL, has raised £2.8m to develop optical sensing technology to help heart disease patients in a grey zone where the need for treatment is unclear.
Echopoint has raised its investment from the UCL Technology Fund, Parkwalk and two grants from Innovate UK. It will use the funding to further develop the optical fibre sensors on its microcatheters, as well as its unique technology platform which translates their ultrasound signals into meaningful metrics. The company will also complete a 20-30 patient clinical trial.
Echopoint spun-out from UCL earlier this year and has since been awarded the Innovators Award at the UCL Awards for Innovation & Enterprise, for its commitment to commercialisation activities. UCLB has been working alongside the Echopoint team throughout their journey towards commercialisation, providing planning support, company formation and intellectual property advice.
Dr Weng Sie Wong, Senior Business Manager, UCLB, says: “We are excited to be working alongside the Echopoint team who are leaders in their fields of expertise. I look forward to seeing how they further develop Echopoint’s technology platform with the funding raised.”
Read more about the story in The Telegraph